David Silberman
CIK: 0001867998
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Silberman David
Silberman David (SEC CIK 0001867998) files insider reports with the SEC as Chief Financial Officer of COMPUGEN LTD (CGEN) and Director of Nasus Pharma Ltd (NSRX).
Signal8 holds 3 ownership filings by Silberman David (2 Form 3, 1 Form 4), filed between Mar 18, 2026 and Jul 30, 2026. Those filings report 1 transaction, the latest on Jul 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Silberman David's filings is in HOLON.
Recent filings by Silberman David
- Jul 29, 2026: Grant or award of CGEN shares (Form 4, code A).
Other insiders filing for COMPUGEN LTD (CGEN)
- Levine Zurit, SVP, Business Development
- Ophir Eran, President and CEO
- Cohen-Dayag Anat, Director
- Perry Eran, Director
- Ferre Pierre, Chief Operating Officer
- Kredo Russo Sharon, SVP, Research & Discovery